Chris Ryan

Wendy Stock, MD, details key recommendations from the 2026 ASH guidelines for adolescent/young adult acute lymphoblastic leukemia management.

Glofitamab combined with CAR T-cell therapy is associated with improved outcomes in relapsed/refractory B-cell lymphoma.

Obe-cel is associated with durable survival outcomes in relapsed/refractory B-ALL, regardless of BOR of CR or CRi.

Selinexor plus ruxolitinib met the SVR co–primary end point but missed the symptom score end point in the phase 3 SENTRY trial in myelofibrosis.

Updated data from TRANSCEND FL showed durable efficacy outcomes with liso-cel in relapsed/refractory follicular lymphoma.

Multiple experts weigh in on the potential of MRD as a primary end point following recently issued FDA draft guidance for the end point in myeloma.

Patients with HLA-A*02–negative, HER2-positive early breast cancer experienced a recurrence rate of less than 1% when treated with GLSI-100.GLSI-100

Retrospective data showed longer durations of bridging therapy with a BTK inhibitor improved CAR T-cell therapy response in relapsed/refractory DLBCL.

Will the FDA approve bezuclastinib for the treatment of patients with nonadvanced systemic mastocytosis?

Venetoclax plus decitabine/cedazuridine after a venetoclax-based RIC regimen was effective and safe in myelodysplastic syndromes or acute myeloid leukemia.

The EMA has received a Type II variation application seeking the approval of teclistamab for relapsed/refractory multiple myeloma after 1 line of therapy.

Data from China showed relma-cel yielded durable responses in patients with relapsed/refractory mantle cell lymphoma.

Mezigdomide plus carfilzomib and dexamethasone improved progression-free survival in relapsed/refractory multiple myeloma.

Giredestrant plus palbociclib did not yield a statistically significant PFS improvement in ER-positive/HER2-negative locally advanced or metastatic breast cancer.

Zovegalisib plus fulvestrant drove responses in HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer

The FDA has approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Allo-HSCT did not improve survival outcomes in patients with lower-risk myelodysplastic syndrome who had some higher-risk features.

Will the FDA approve rusfertide for the treatment of adult patients with polycythemia vera?

In an OncLive Ask the Expert program, Sagar Lonial, MD, FACP, FASCO, outlined how CELMoDs may be integrated into multiple myeloma care.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Gurbakhash Kaur, MD, discusses the exploration of CELMoDs in multiple myeloma care and how they may affect the treatment paradigm.

The FDA expanded the indication for zongertinib in unresectble or metastatic nonsquamous NSCLC harboring HER2 TKD mutations.

An analysis showed the manufacturing and distribution of Orca-T was consistent for patients with hematologic malignancies.

Luspatercept generated favorable efficacy and safety outcomes in the treatment of anemia in patients with transfusion-dependent, lower-risk MDS.

An ML-NMR analysis associated zanubrutinib with PFS improvements vs ibrutinib or acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses 4-year data from the PATHFINDER trial of avapritinib in advanced systemic mastocytosis.

Orca-Q produced to high engraftment rates and promising survival outcomes in high-risk hematologic malignancies with haploidentical donors.

Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.

Orca-T was associated with OS, RFS, and NRM improvements in patients with hematologic malignancies who also received myeloablative conditioning.

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.